Gain Therapeutics, Inc.
GANX · Nasdaq · United States
Share price · GANX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when GANX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026+25.5%
- 5 Nov 2026-13.5%
Nothing announced by GANX that day or the session before.
- 26 Oct 2026-8.7%
Nothing announced by GANX that day or the session before.
- 22 Oct 2026+8.4%
Nothing announced by GANX that day or the session before.
- 11 Aug 2026+16.4%
- 21 Jul 2026+12.9%
Nothing announced by GANX that day or the session before.
- 29 Jun 2026+13.1%
Nothing announced by GANX that day or the session before.
- 28 May 2026+14.1%
Nothing announced by GANX that day or the session before.
- 18 Mar 2026-25.6%
Nothing announced by GANX that day or the session before.
- 6 Mar 2026+21.5%
Nothing announced by GANX that day or the session before.
Share of unusual movement by asset
For each asset, the share of GANX's own-move activity since 3 Nov 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 9% |
| Sessions with no dated event | — | 91% |
No dated announcements about its assets since 3 Nov 2025.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | GBA1/glucocerebrosidaseSmall molecule | Parkinson's Disease |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $1.4M | $12M | $3.2M-$3.0M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $2.1M | $13M | $4.7M-$4.7M operating cash flow | report ↗ |
| 2026-Q1 | — | $2.8M | $17M | $5.6M-$4.7M operating cash flow | report ↗ |
| 2025-Q3 | — | $2.9M | $8.8M | $5.3M-$4.9M operating cash flow | report ↗ |
| 2025-Q2 | — | $2.8M | $6.7M | $5.8M-$5.1M operating cash flow | report ↗ |
| 2025-Q1 | — | $2.3M | $9.1M | $4.5M-$3.8M operating cash flow | report ↗ |
| 2024-Q3 | — | $2.6M | $12M | $4.5M-$6.1M operating cash flow | report ↗ |
| 2024-Q2 | — | $4.4M | $17M | $8.1M-$5.8M operating cash flow | report ↗ |
| 2024-Q1 | — | $2.5M | $11M+ $2.0M short-term inv. | $4.0M-$3.6M operating cash flow | report ↗ |
| 2023-Q3 | — | $2.4M | $4.3M+ $8.0M short-term inv. | $4.7M-$4.0M operating cash flow | report ↗ |
| 2023-Q2 | — | $4.0M | $6.3M+ $9.9M short-term inv. | $7.7M-$5.0M operating cash flow | report ↗ |
| 2023-Q1 | $0.1M | $2.8M | $6.0M+ $12M short-term inv. | $5.1M-$4.2M operating cash flow | report ↗ |
| 2022-Q3 | — | $2.0M | $11M+ $12M short-term inv. | $4.6M-$3.3M operating cash flow | report ↗ |
| 2022-Q2 | $0.1M | $2.6M | $14M+ $9.9M short-term inv. | $5.1M-$5.0M operating cash flow | report ↗ |
| 2022-Q1 | $0.1M | $1.6M | $34M | $3.3M-$2.5M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $10M | $21M | $5.0M-$18M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $11M | $10M | $5.1M-$19M operating cash flow | report ↗ |
| 2023-FY | $0.1M | $12M | $12M+ $5.0M short-term inv. | $5.6M-$19M operating cash flow | report ↗ |
| 2022-FY | $0.1M | $8.4M | $7.3M+ $13M short-term inv. | $4.4M-$15M operating cash flow | report ↗ |
| 2021-FY | $0.2M | $7.2M | $37M | $3.5M-$12M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-29 | Weidner Jeanette · See Remarks | Award / grant (derivative) | 130,000 | — | — | Form 4 |
| 2026-07-15 | HASLER HANS PETER · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-07-15 | Riley Jeffrey Scott · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-07-15 | Melincoff Gwen A · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-07-15 | Islam Khalid · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-07-15 | Nicaise Claude · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-07-15 | GOLDSTEIN DOV A MD · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-03-24 | Fuggetta Gianluca · See Remark | Award / grant (derivative) | 50,000 | — | — | Form 4 |